MedTrace Logo

Hepaxa Management of Non-alcoholic Fatty Liver Disease

NCT03801577 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-01-11

No results posted yet for this study

Summary

This study measures the steatosis in patients With fatty livers as determined by CAP score from a fibroscan assessment. The study attempts to determine the effect of using the Medical Food Hepaxa in a Clinical setting Close to real-world use.

Conditions

  • Non-Alcoholic Fatty Liver Disease
  • Non Alcoholic Fatty Liver
  • NASH - Nonalcoholic Steatohepatitis

Interventions

DIETARY_SUPPLEMENT

Hepaxa

High concentrate EPA and DHA

Sponsors & Collaborators

  • BASF AS

    lead INDUSTRY

Principal Investigators

  • Reed Hogan, MD · GI Associates and Endoscopy Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-28
Primary Completion
2019-10-31
Completion
2019-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03801577 on ClinicalTrials.gov